These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29722658)

  • 41. Discussion.
    J Am Coll Surg; 2014 Jul; 219(1):120-1. PubMed ID: 24952448
    [No Abstract]   [Full Text] [Related]  

  • 42. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions.
    Antoniou G; Kountourakis P; Papadimitriou K; Vassiliou V; Papamichael D
    Cancer Treat Rev; 2014 Feb; 40(1):78-85. PubMed ID: 23810287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
    Schwarz L; Katz MH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant therapy for resectable pancreatic cancer.
    Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
    Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Ferrone CR
    Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
    Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Resection for advanced pancreatic cancer following multimodal therapy].
    Kleeff J; Stöß C; Yip V; Knoefel WT
    Chirurg; 2016 May; 87(5):406-12. PubMed ID: 27138271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?
    Halperin DM; Varadhachary GR
    Curr Oncol Rep; 2014 Feb; 16(2):366. PubMed ID: 24445498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications.
    Verma V; Li J; Lin C
    Am J Clin Oncol; 2016 Jun; 39(3):302-13. PubMed ID: 26950464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hope and frustration of neoadjuvant chemotherapy for resectable pancreatic cancer].
    Lu C; Miao Y; Gao WT
    Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):813-816. PubMed ID: 30392300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Surgical Planning for "Borderline Resectable" and "Locally Advanced" Pancreatic Cancer During Open Pancreatic Resection.
    Tamburrino D; De Stefano F; Belfiori G; Partelli S; Crippa S; Falconi M
    J Gastrointest Surg; 2023 Dec; 27(12):3014-3023. PubMed ID: 37783912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pancreatic cancer: advances in treatment.
    Mohammed S; Van Buren G; Fisher WE
    World J Gastroenterol; 2014 Jul; 20(28):9354-60. PubMed ID: 25071330
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit?
    Ren L; Mota Reyes C; Friess H; Demir IE
    Langenbecks Arch Surg; 2020 Nov; 405(7):879-887. PubMed ID: 32776259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer.
    Laurence JM; Tran PD; Morarji K; Eslick GD; Lam VW; Sandroussi C
    J Gastrointest Surg; 2011 Nov; 15(11):2059-69. PubMed ID: 21913045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in the treatment of pancreatic cancer in Japan.
    Matsuki R; Arai T; Kogure M; Suzuki Y; Sakamoto Y
    Biosci Trends; 2021 Jul; 15(3):135-137. PubMed ID: 33776020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.